Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.86 USD | -1.76% | -0.66% | -23.94% |
05-16 | Sartorius sinks again towards year low | DP |
05-16 | Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 55.15 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.94% | 20.66B | - | ||
-5.06% | 182B | C+ | ||
-0.05% | 114B | C | ||
-5.75% | 67.76B | A | ||
+1.99% | 51.91B | B- | ||
+7.28% | 43.23B | B- | ||
+6.07% | 41.07B | B+ | ||
+22.60% | 32.07B | B | ||
+15.86% | 25B | A- | ||
-4.03% | 24.55B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DIM Stock
- SRTOY Stock
- Ratings Sartorius Stedim Biotech S.A.